A Phase 2 interventional study of pemetrexed and cisplatin in Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Terminated at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-05-29.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing cisplatin in Small Cell Lung Carcinoma — 2 open to participants now, 2 under way, none of them phase 3. Cisplatin · Small Cell Lung Carcinoma.
Among the 33 studies testing cisplatin in Small Cell Lung Carcinoma, this one is the 30th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2007, is one of 15 in phase 2, and was the 19th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →2 of the 33 studies testing cisplatin in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Ages 18–70
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 8
First in 1999; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 62 across the 32 interventional studies. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 33 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company: none open now, 1 under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company, this one is the 11th largest by enrollment, is one of 3 that started in 2007, is one of 5 in phase 2, and was the 5th registered.
Eli Lilly and Company’s Small Cell Lung Carcinoma studies by the year they started, since 1998.
1 of the studies testing cisplatin in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838208Anhui Provincial Cancer HospitalTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies testing cisplatin in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 12 in Small Cell Lung Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if cisplatin and pemetrexed are effective in the treatment of patients with Small Cell Lung Cancer, extended disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed · Drug: cisplatin
500 mg/m2, intravenous (IV), every 21 days x 6 cycles
Also known as: LY231514, Alimta
75 mg/m2, intravenous (IV), every 21 days x 6 cycles
Overall Response Rate
Trial terminated - results not analyzed
Time frame: baseline to measured progressive disease
Overall Survival
Trial terminated - results not analyzed
Time frame: baseline to date of death from any cause
Progression Free Survival
Trial terminated - results not analyzed
Time frame: baseline to measured progressive disease
Duration of Response
Trial terminated - results not analyzed
Time frame: time of response to progressive disease
Stable Disease Rate
Trial terminated - results not analyzed
Time frame: baseline to measured progressive disease
| Milestone | Pemetrexed + Cisplatin |
|---|---|
| Started | 5 |
| Completed | 1 |
| Not completed | 4 |
| Withdrew: Death | 1 |
| Withdrew: Sponsor's decision | 3 |
Trial terminated - results not analyzed
No measurements were reported for this outcome.
Trial terminated - results not analyzed
No measurements were reported for this outcome.
Trial terminated - results not analyzed
No measurements were reported for this outcome.
Trial terminated - results not analyzed
No measurements were reported for this outcome.
Trial terminated - results not analyzed
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | — | — |
| Event | Pemetrexed + Cisplatin |
|---|---|
| DiarrhoeaGastrointestinal disorders | 1/5 |
| Renal failure acuteRenal and urinary disorders | 1/5 |
| PyrexiaGeneral disorders | 1/5 |
| DysphagiaGastrointestinal disorders | 1/5 |
| Event | Pemetrexed + Cisplatin |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/5 |
| AstheniaGeneral disorders | 1/5 |
| Gamma-glutamyltransferase increasedInvestigations | 1/5 |
| Blood creatine increasedInvestigations | 1/5 |
| LeukopeniaBlood and lymphatic system disorders | 1/5 |
| LymphopeniaBlood and lymphatic system disorders | 1/5 |
| NauseaGastrointestinal disorders | 1/5 |
| HypokalaemiaMetabolism and nutrition disorders | 1/5 |
| Inappropriate antidiuretic hormone secretionEndocrine disorders | 1/5 |
| Age Continuous(years) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 66.6 ± 5.9 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin |
|---|---|
| Female | 0 |
| Male | 5 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin |
|---|---|
| Spain | 5 |
| Race/Ethnicity(participants) | Pemetrexed + Cisplatin |
|---|---|
| Caucasian | 5 |
| Height(centimeters) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 163.9 ± 4.2 |
| Weight(kilograms) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 76.0 ± 5.9 |
The record gives a start of Oct 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin